@article{10902/32792,
year = {2022},
url = {https://hdl.handle.net/10902/32792},
abstract = {Teriflunomide, sold under the brand name Aubagio®, is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with remitting relapsing multiple sclerosis (rrMS) (1). This drug exhibits a favourable safety profile and is well tolerated by most patients (2). Most common adverse events include hair thinning, mild lymphocytopenia and headache (2). We report the first case of teriflunomide-associated Raynau's phenomenon},
publisher = {Springer Verlag},
publisher = {Neurological Sciences, 2022, 43, 6593-6594},
title = {Teriflunomide-induced Raynaud's phenomenon: a serious adverse event, previously unreported},
author = {Riancho Zarrabeitia, Javier and Delgado Alvarado, Manuel and Riancho Zarrabeitia, Leyre},
}